Business profile

Haka Pharma Oy

Haka Pharma Oy's registered office is Helsingfors. It is a limited company. The company was established on 2019-02-18. It operates in the industry of other financial service activities, except insurance and pension funding n.e.c.. In its latest retained statement for 2025-12-31, revenue was €533,459 and operating profit was €130,015.

Claim profileContact details
Business ID 2972478-2ValidUnclaimed company profile

Trusted core data

Public company details from the trade register.

Business ID
2972478-2
Sector
Other financial service activities, except insurance and pension funding n.e.c.
Municipality
Helsingfors
Company form
Limited company
Registration date
2019-02-18
Business ID registration date
2019-01-28
Business status
Valid
Profile ownership
Unclaimed company profile

Contact and location summary

Visiting address: Tähtitorninkatu 16 A 17, 00140, Helsingfors

About Haka Pharma Oy

Financial position and key figures for the company.

Haka Pharma Oy's location municipality is Helsingfors. It is a limited company. The company was established on 2019-02-18. It operates in the industry of other financial service activities, except insurance and pension funding n.e.c.. In its latest retained statement for 2025-12-31, revenue was €533,459 and operating profit was €130,015. The latest retained financial statement for 2025-12-31 shows revenue of €533,459 and profit for the financial year of €95,991. Based on the latest retained statement, revenue growth was -75.5%, operating margin was +24.4%, and equity ratio was +99.8%.

Financial highlights

Key figures from the latest financial period.

Open full statement
Latest financial period

2025-12-31

Imported periods5
PRH parsed3
Profile sourcePRH/XBRL financial statement
Derived indicators
Revenue growth-75.5%
Operating margin24.4%
Equity ratio99.8%
Revenue€533,459-€1,647,436 (-75.5%) vs previous periodPrevious: €2,180,894
Operating profit (loss)€130,015-€408,303 (-75.8%) vs previous periodPrevious: €538,318
Profit (loss) for the financial year€95,991-€343,978 (-78.2%) vs previous periodPrevious: €439,969
Assets€1,930,394-€154,206 (-7.4%) vs previous periodPrevious: €2,084,600
Balance-sheet contextLatest financial period
Other operating income€30,720Previous: €29,898
Inventory€0Previous: €131,889
Cash and bank€181,974Previous: €462,597
Retained earnings€1,827,584Previous: €1,537,614
Equity€1,926,075Previous: €1,980,084
Liabilities€4,319Previous: €104,516
Current assets€920,911Previous: €1,179,910
Current liabilities€4,319Previous: €104,516
Revenue trend3 periods
€2,183,992
2023-12-31
€2,180,894
2024-12-31
€533,459
2025-12-31
Operating profit (loss) trend3 periods
€557,290
2023-12-31
€538,318
2024-12-31
€130,015
2025-12-31
Profit (loss) for the financial year trend3 periods
€455,444
2023-12-31
€439,969
2024-12-31
€95,991
2025-12-31
Assets trend3 periods
€1,813,268
2023-12-31
€2,084,600
2024-12-31
€1,930,394
2025-12-31

Financial ratios

Financial ratios based on financial statement data. Source: PRH/XBRL-tilinpäätös.

Equity ratioGood
100/100 · Improving
99.8 %2024-12-31: 95.0 %
Current ratioGood
100/100 · Improving
42.13x2024-12-31: 5.69x
Operating profit marginGood
100/100 · Declining
23.1 %2024-12-31: 24.4 %
Ratio history
Ratio2023-12-312024-12-312025-12-31
Equity ratio92.4 %95.0 %99.8 %
Current ratio4.33x5.69x42.13x
Operating profit margin25.3 %24.4 %23.1 %

Registry status and identifiers

Current registry information and identifiers based on YTJ data.

YTJ statusValid
Trade RegisterRegistered
Business ID2972478-2
EU IDFIFPRO.2972478-2
MunicipalityHelsingfors
Current registered entries
2019-02-18Registered in Patent and Registration Office (Trade Register)
2019-02-19Registered in Tax Administration (Tax Administration)

Risk certificate

An open-data based company stability and risk signal.

BUSINESS.fi

BUSINESS.fi Luottoluokitus

Profile-specific risk signal based on open data

Automatic gradeNot a credit decision
A2
Very goodHaka Pharma Oy
Grade upgradedA3 → A2 · new analysis 2026-10-01
Model score82/100
Assessment confidenceHigh
Evidence qualityStrong financial evidenceFinancial data included
Financial trajectoryFinancial development is mostly stable or mixed.
3 comparable periods
RevenueDeteriorating
ProfitabilityStable
SolvencyStable
LiquidityImproving · 2 consecutive periods
Peer comparisonSame size nationallyDescriptive comparison – does not change the model score.
115 peers
Solvency98%
Better than 98% of peers
Profitability79%
Better than 79% of peers
Liquidity99%
Better than 99% of peers
Revenue growth0%
Below 100% of peers
Financial statement reporting patternRegularBased on observed PRH financial period end and registration dates. This descriptive evidence does not change the v0.14 score.
4 observed filings
Latest registration lag83 days after period end
Typical registration lag84 days after period end
Annual continuity4 consecutive periods
Supporting factors
  • Strong equity ratio
  • Strong operating profitability
  • Healthy short-term liquidity
Risk factors to note
  • Sharp year-over-year revenue drop
Rating historyAutomatic assessment developmentChanges are derived from evidence differences between persisted automatic assessments.
4 assessments
A2
2026-10-01 07:2382/100 · v0.14
A3 → A2 · +10 points
  • Evidence strengthened: a PRH/XBRL financial statement was added to the assessment (2025-12-31).
  • Assessment confidence: Medium → High.
  • Evidence quality: Registry and statistical evidence → Strong financial evidence.
A3
2026-09-1572/100 · v0.14
B1 → A3 · +9 points
  • Assessment confidence: Low → Medium.
  • Evidence quality: Registry and statistical evidence → Registry and statistical evidence.
  • New risk factor: Sufficient structured financial metrics are not available.
B1
2026-09-1463/100 · v0.12
Oldest retained automatic assessment in this comparison
Automatic model gradeA2
Automatic model snapshot2026-10-01
Automatic model versionopen-risk-grade-v0.14
Financial data included

The grade can use open digital financial statement data together with registry signals.

Verify assessment

Risk context

When sufficient source-backed financial metrics are not available for a Tier 1 assessment, BUSINESS.fi shows registry, industry, and regional context.

Industry riskvery low
89/100

Industry context is very low based on normalized open statistical inputs.

Age and continuityHyvä
60/100

The company has about 7 years of registry continuity.

Registry and status signalsSeurattava
62/100

Registry history, filing recency, and active register markings are still limited or mixed.

Events & news

Verified events and sourced external company news in one timeline.

Risk grade updatedRisk gradeEvidence verified
1 Oct 2026 · BUSINESS.fi / Opterom LuottoluokitusAutomatic grade A3 → A2.
Risk grade updatedRisk gradeEvidence verified
15 Sept 2026 · BUSINESS.fi / Opterom LuottoluokitusAutomatic grade A3.
Risk grade updatedRisk gradeEvidence verified
14 Sept 2026 · BUSINESS.fi / Opterom LuottoluokitusAutomatic grade B1.

Registry timeline

Trade register notifications shown on a timeline.

11 register eventsLatest event: 2026-03-24

Financial statements availability

Available financial statement periods and PRH source filings.

5 financial statement periodsLatest financial period: 2025-12-31

Profile source and ownership

Profile based on public registry data
BUSINESS.fi has created this profile from public company information. Source data updated 2025-12-31.

This company profile has not been claimed yet

Haka Pharma Oy shows public core facts. A company representative can claim the profile, update public information, and access owner tools.